MIV Therapeutics Subsidiary Invited to Present Groundbreaking Stroke-Prevention Device at Top International Symposium; SagaX to Spotlight Latest Developments to Commercialize Unique Implantable Embolic Filter at TCT2006 Conference.

ATLANTA -- MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that its SagaX subsidiary has been invited to present its advanced technologies at the 18th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics (TCT) 2006, one of the world's leading gatherings of cardiovascular professionals.

TCT2006 is the Cardiovascular Research Foundation's (CRF) annual symposium, where distinguished CRF faculty joins with hundreds of the world's leading cardiologists to teach, share and discuss the latest techniques and developments in the field with some 11,000 symposium participants from around the globe.

SagaX is developing an Aortic Embolic Protection Device (AEPD) that can be placed in the aorta - a main artery sending blood to the brain - to filter and capture embolic particles that can cause strokes. The filtration is designed to prevent embolic particles such as blood clots from traveling in the direction of the patient's brain, where they can cut off blood flow, triggering strokes in minutes. Such emboli are one of the chief causes of strokes.

"This presentation is an ideal platform to demonstrate the potential advantages of the AEPD to some of the world's most influential cardiovascular researchers and specialists," said Dr. Dov Shimon, Chief Medical Officer of MIVT, who founded SagaX and leads its research and development. "I believe the invitation is indicative of the need for these solutions and our leadership to reduce the serious threat of stroke during cardiovascular procedures."

The AEPD is designed to be implanted during invasive heart procedures such as electrophysiology, valve dilatations and valve repair through angioplasty. It may also find broad preventative applications through other minimally invasive alternatives to surgery.

Recently, MIVT filed three patent applications that cover different types of device refinements, including configurations and the use of different filtration technologies, further strengthening its intellectual property portfolio.

SagaX is scheduled to present on October 26, 2006, during the symposium on "Innovative Devices and Futuristic Therapies." TCT is the world's premier gathering where the latest trends, research findings, and techniques in interventional vascular medicine are disseminated to practicing physicians from around the world. The symposium will feature live procedures originating from 31 U.S. and international medical centers featuring world-renowned operators performing complex interventions. Cases will be presented with an interactive and thematic approach, rather than simply showcasing techniques or devices.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.